India Equity Analysis, Reports, Recommendations, Stock Tips and more!
Search Now
Recommendations
Showing posts with label Cadila Healthcare. Show all posts
Showing posts with label Cadila Healthcare. Show all posts
Tuesday, April 08, 2014
Thursday, March 27, 2014
Thursday, August 16, 2012
Sunday, March 25, 2012
Monday, February 13, 2012
Wednesday, November 16, 2011
Sunday, November 13, 2011
Sunday, January 30, 2011
Cadila Healthcare
Good results, bright prospects in the domestic and export markets and better growth expectations from its joint venture companies make Cadila Healthcare a good investment bet for the long-term.
At the current market price of Rs 812, the stock trades at about 21 times its likely FY-12 per share earnings.
Thursday, January 20, 2011
Thursday, October 21, 2010
Wednesday, October 20, 2010
Thursday, July 01, 2010
Sunday, June 06, 2010
Tuesday, May 04, 2010
Sunday, May 02, 2010
Cadila Healthcare
Investors with a long-term perspective can consider taking exposure to the stock of Cadila Healthcare.
The company's strong product pipeline, expected contributions from its Hospira joint venture and a strengthening presence in the high-margin domestic consumer markets (through its listed subsidiary Zydus Wellness) point towards healthy growth potential over the long term.
Cadila's improving focus on the domestic pharmaceutical market through product launches, in-licensing arrangements, and a special focus on rural markets also promise further growth in the domestic market.
At current market price of Rs 564, the stock trades at an expected FY-11 price earnings multiple of about 19 times. This appears reasonable given its long-term growth potential.
Possible triggers from its R&D pipeline and the commercial launch of H1N1 drug can also provide further upside to the stock price. Investors may, however, consider a phased accumulation of the stock.
For the coming year, the management has given a guidance of $1 billion revenues. It expects growth to be driven by international revenues, largely helped by its presence in the US. Given the company's robust regulatory pipeline of 106 abbreviated new drug application (ANDA) filings and 90 drug master files (DMFs), and its focus on filing for niche, difficult-to-make products, a ramp up in US generic revenues may not be difficult to achieve. Cadila plans to file 12-15 ANDAs annually for the US market each year. For the year ended March 2010, it received 12 ANDA approvals, taking the total to 54.
New product launches and improvement in the market share of existing products would help push US revenues; introduction of generic version of Flomax providing significant revenue opportunity. Overall, Cadila's export formulations business reported a 45 per cent revenue growth last year. Domestic revenues, which grew by over 12 per cent in FY10, are expected to expand by 15 per cent in the coming year.
Cadila's joint venture with Nycomed, which supplies final active ingredient for Pantoprazole drug, is expected to see a fall in revenues in the next couple of years (as the drug is set to lose patent by February 2011 in the US).
However, the extent of fall in revenues may not be drastic since the company will soon start the supply of 14 new Active Pharmaceutical Ingredients (APIs).
The recent US court ruling upholding the patent on Pantoprazole drug too may provide a short-term reprieve, given the possibility of a fall in sales from Teva and Sun Pharmaceuticals.
The ramp up in production by its joint venture with Hospira will also provide further long-term thrust.
via BL
Saturday, May 01, 2010
Monday, April 19, 2010
Wednesday, March 31, 2010
Tuesday, December 22, 2009
Subscribe to:
Posts (Atom)